We also suspect the contribution of resistance mechanisms independent of the E‐cadherin–CD103 interaction, as inhibition of TGF‐β signaling minimized resistance to CTL‐mediated killing without apparent changes in expression of E‐cadherin in Mes cancer clones (Terry et al., 2017). The gene discussed is TGFB1; the disease is Meckel syndrome, type 1.